Nordic registries (n=13,872): D2T-PsA varied 37% (≥2 b/tsDMARDs failed) to 0.6% (strictest). Female predominance increased with therapy failures (≥4 failures: 67% female). Median time to failure: 5–7 years. Abstract OP0177 @RheumNow #EULAR2025 https://t.co/lchPnTCEx7